Vidofludimus

Vidofludimus
Legal status
Legal status
  • Investigational
Identifiers
  • 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.112.872
Chemical and physical data
FormulaC20H18FNO4
Molar mass355.365 g·mol−1
3D model (JSmol)
  • COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
  • InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
  • Key:XPRDUGXOWVXZLL-UHFFFAOYSA-N

Vidofludimus is an investigational new drug that is being evaluated to treat Crohn's disease and ulcerative colitis.[1] It is a dihydroorotate dehydrogenase inhibitor.[2]

References

  1. ^ "Vidofludimus calcium - Immunic". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Muehler A, Peelen E, Kohlhof H, Gröppel M, Vitt D (August 2020). "Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis". Multiple Sclerosis and Related Disorders. 43: 102129. doi:10.1016/j.msard.2020.102129. PMID 32428844.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.